This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Gossamer Bio Trial Failure, Fraud...
Business securities fraud investigation

Gossamer Bio Trial Failure, Fraud Investigation

Analysis based on 13 articles · First reported Feb 26, 2026 · Last updated Mar 12, 2026

Sentiment
-40
Attention
2
Articles
13
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of Gossamer Bio's failed drug trial and the subsequent securities fraud investigation, leading to a significant drop in Gossamer Bio's stock price. This event highlights the risks associated with pharmaceutical development and potential corporate misconduct.

Biotechnology Legal
Event Summary

Gossamer Bio announced on February 23, 2026, that its Phase 3 PROSERA trial, evaluating Seralutinib for pulmonary arterial hypertension, failed to meet its primary endpoint. This announcement caused Gossamer Bio's stock price to plummet by 80.14%, closing at $0.423 per share. Following this significant drop, Pomerantz LLP initiated an investigation into whether Gossamer Bio and its officers/directors engaged in securities fraud or other unlawful business practices.

Key Actions
100 Gossamer Bio announced Phase 3 trial failure
90 Gossamer Bio stock price fell
80 Pomerantz LLP initiated securities fraud investigation Gossamer Bio
Entities Involved
stock
Gossamer Bio
Gossamer Bio's stock price fell significantly after its Phase 3 PROSERA trial failed to meet its primary endpoint. This failure led to an investigation into potential securities fraud.
Importance 100 Sentiment -90
priv
Pomerantz LLP
Pomerantz LLP is initiating a class action lawsuit against Gossamer Bio, representing investors who may have been victims of securities fraud.
Importance 60 Sentiment 20
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.